| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
1,148 |
1,097 |
$210K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
1,011 |
931 |
$202K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
793 |
719 |
$173K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
1,805 |
1,504 |
$12K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
24 |
24 |
$9K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
191 |
139 |
$9K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
120 |
116 |
$9K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
906 |
748 |
$7K |
| 80053 |
Comprehensive metabolic panel |
706 |
638 |
$7K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
565 |
488 |
$5K |
| 87631 |
|
26 |
26 |
$3K |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
137 |
133 |
$3K |
| 71046 |
Radiologic examination, chest; 2 views |
261 |
249 |
$3K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
200 |
186 |
$3K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
98 |
56 |
$2K |
| 84484 |
|
238 |
162 |
$2K |
| 81001 |
|
600 |
551 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
29 |
28 |
$1K |
| 80076 |
|
103 |
73 |
$715.48 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
56 |
28 |
$661.68 |
| 81025 |
|
92 |
76 |
$617.33 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
39 |
38 |
$519.78 |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
15 |
15 |
$480.15 |
| 71045 |
Radiologic examination, chest; single view |
27 |
27 |
$267.23 |
| 84600 |
|
15 |
12 |
$261.15 |
| 81003 |
|
94 |
84 |
$198.33 |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
12 |
12 |
$148.80 |
| 83690 |
|
24 |
24 |
$145.72 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
13 |
12 |
$12.01 |
| 36415 |
Collection of venous blood by venipuncture |
827 |
554 |
$1.62 |